|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADAMTS5 |
Gene summary for ADAMTS5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADAMTS5 | Gene ID | 11096 |
| Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 5 | |
| Gene Alias | ADAM-TS 11 | |
| Cytomap | 21q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000768 | UniProtAcc | Q9UNA0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11096 | ADAMTS5 | ATC13 | Human | Thyroid | ATC | 6.21e-57 | 1.69e+00 | 0.34 |
| 11096 | ADAMTS5 | ATC2 | Human | Thyroid | ATC | 3.27e-02 | 1.44e-01 | 0.34 |
| 11096 | ADAMTS5 | ATC5 | Human | Thyroid | ATC | 5.95e-74 | 1.78e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002241124 | Thyroid | ATC | cellular component disassembly | 248/6293 | 443/18723 | 1.34e-22 | 3.69e-20 | 248 |
| GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
| GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
| GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
| GO:004269216 | Thyroid | ATC | muscle cell differentiation | 165/6293 | 384/18723 | 7.17e-05 | 5.46e-04 | 165 |
| GO:010610621 | Thyroid | ATC | cold-induced thermogenesis | 68/6293 | 144/18723 | 4.70e-04 | 2.76e-03 | 68 |
| GO:012016121 | Thyroid | ATC | regulation of cold-induced thermogenesis | 68/6293 | 144/18723 | 4.70e-04 | 2.76e-03 | 68 |
| GO:199084521 | Thyroid | ATC | adaptive thermogenesis | 71/6293 | 157/18723 | 1.59e-03 | 7.99e-03 | 71 |
| GO:005114617 | Thyroid | ATC | striated muscle cell differentiation | 119/6293 | 283/18723 | 1.74e-03 | 8.70e-03 | 119 |
| GO:000165912 | Thyroid | ATC | temperature homeostasis | 73/6293 | 174/18723 | 1.29e-02 | 4.51e-02 | 73 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADAMTS5 | SNV | Missense_Mutation | rs765880915 | c.1340A>T | p.Asp447Val | p.D447V | Q9UNA0 | protein_coding | deleterious(0) | possibly_damaging(0.595) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ADAMTS5 | SNV | Missense_Mutation | c.1266T>A | p.Asp422Glu | p.D422E | Q9UNA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.666) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADAMTS5 | SNV | Missense_Mutation | c.275A>T | p.Tyr92Phe | p.Y92F | Q9UNA0 | protein_coding | tolerated(0.24) | probably_damaging(0.988) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR | |
| ADAMTS5 | SNV | Missense_Mutation | rs753190231 | c.2624N>T | p.Ser875Leu | p.S875L | Q9UNA0 | protein_coding | tolerated(0.41) | benign(0.01) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTS5 | SNV | Missense_Mutation | novel | c.1275N>A | p.Phe425Leu | p.F425L | Q9UNA0 | protein_coding | tolerated(0.67) | possibly_damaging(0.706) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTS5 | SNV | Missense_Mutation | rs142161826 | c.1430N>A | p.Arg477Gln | p.R477Q | Q9UNA0 | protein_coding | tolerated(0.89) | benign(0.007) | TCGA-AN-A0XO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ADAMTS5 | SNV | Missense_Mutation | c.940N>C | p.Ala314Pro | p.A314P | Q9UNA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.485) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ADAMTS5 | SNV | Missense_Mutation | c.1648N>A | p.Gln550Lys | p.Q550K | Q9UNA0 | protein_coding | tolerated(0.59) | benign(0.024) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADAMTS5 | SNV | Missense_Mutation | novel | c.1350N>T | p.Lys450Asn | p.K450N | Q9UNA0 | protein_coding | tolerated(0.48) | probably_damaging(0.91) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTS5 | SNV | Missense_Mutation | novel | c.1350N>T | p.Lys450Asn | p.K450N | Q9UNA0 | protein_coding | tolerated(0.48) | probably_damaging(0.91) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11096 | ADAMTS5 | DRUGGABLE GENOME, ENZYME, PROTEASE, NEUTRAL ZINC METALLOPEPTIDASE | inhibitor | 252166754 | ||
| 11096 | ADAMTS5 | DRUGGABLE GENOME, ENZYME, PROTEASE, NEUTRAL ZINC METALLOPEPTIDASE | AGG-523 | AGG-523 | ||
| 11096 | ADAMTS5 | DRUGGABLE GENOME, ENZYME, PROTEASE, NEUTRAL ZINC METALLOPEPTIDASE | TUMOR NECROSIS FACTOR | 11520168 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |